Market reporting

#Europe #Investment #Market reporting #Survey

European biopharma investment confidence increasing, c-suite survey reveals

Biopharma dealmaking confidence is strengthening, a new survey has revealed, but access to capital remains the defining challenge.  BIO-Europe’s Biopharma C-Suite Agenda Survey 2026 surveyed 81 senior biopharma executives, including 50 CEOs.  The survey results demonstrate that 75% expect partnering and M&A appetite to increase over the next 12 months,… Read More

#Business & Investment #Editor's Choice #News

Eli Lilly Gateway Labs in South San Francisco, California.
#Eli Lilly #GLP-1 #Market reporting #Norstella

New index reveals Eli Lilly as the top ranked company

Norstella has announced the launch of the Pipeline-to-Patient Productivity Index (P3i), a new annual benchmark measuring R&D productivity, market access, and commercial return across the top 25 global biopharma companies.  The P3i is the first benchmark to follow drug performance across the entire development and commercialisation lifecycle. The index is… Read More

#Business & Investment #News #Trending News

Active nerve cells
#AnHorn Medicines #Chemotherapy #Market reporting #Neuropathy #Phase I trial

Phase I study for prevention of chemotherapy-induced peripheral neuropathy

AnHorn Medicines has dosed the first subject in the Phase I clinical trial of AH-008, a first-in-class neuroprotective candidate being developed to prevent chemotherapy-induced peripheral neuropathy (CIPN). This milestone marks the clinical advancement of a novel therapeutic approach designed to address one of the most common and debilitating complications of… Read More

#News

#China #GLP-1 #Market reporting #Metabolic diseases #Obesity #Weight loss

How advanced is China in diabetes drug discovery?

With the largest diabetic population and a pedigree in metabolic diseases, China is becoming one to watch in diabetes and obesity drug discovery. Diana Turner finds out about an increasingly competitive market. Research by clinical research organisation ICON in late 2025 revealed that China is emerging as a ‘global innovation… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Biotech #Drug development #Investment #Market reporting

Treehill Partners: Reflections on JPM and trends for 2026  

DDW Editor Reece Armstrong speaks to Ali Pashazadeh, CEO of capital market company Treehill Partners, about how his experience of this year’s JPM reflects how the industry will move forward in 2026.   The beginning of a new year in drug discovery and development is always marked with the arrival of the JP Morgan Healthcare Conference… Read More

#Business & Investment #Exclusive Content

#Estonia #Latvia #Lithuania #Market reporting

How a new Action Plan is putting the Baltics on the biotech map

Combining cutting-edge science with agile policy, Lithuania, Latvia and Estonia are coming together to create the Baltic Biotech Hub. DDW’s Diana Turner examines this new hotspot for innovation at Life Sciences Baltics 2025.  A new centre for life sciences innovation is growing in a somewhat surprising corner of Europe. The three Baltic states, Lithuania, Latvia and Estonia, are joining forces and combining their complementary… Read More

#Exclusive Content #Market Reports

AI and genomics
#AI / data analytics / healthtech / informatics #Genetics / genomics #Genomics #Market reporting

How are innovations in genomics redefining drug discovery?

Advances in artificial intelligence and synthetic biology are driving a new frontier in genomic research. Megan Thomas explores what the future of genomics will look like. New technologies for the future In a Eureka! podcast interview with McKinsey, Howard Jacob, Vice President of Genomics Research and Head of Data Integration… Read More

#Exclusive Content #Market Reports

#Genetics / genomics #Genomics #Market reporting

How are advances in genomics reshaping drug development?

Megan Thomas provides overview of the global market for genomics, covering its rapid reshaping of drug discovery and development to offer faster, more precise, and cost-effective pathways to new therapies while driving global collaboration and innovation. Past to present As far back as 2000, academic experts were writing in journals… Read More

#Exclusive Content #Market Reports

Tower Bridge, London
#Drug discovery #Events #Investment #London Life Sciences Week #Market reporting

‘Good vibrations’ at London Life Science Week bode well for 2026

Jefferies’ Global Healthcare Conference held every November and coinciding with London Life Science Week (LLSW), is staking its claim as one of the world’s ‘must attend’ biotech investor events – and a vital barometer going into the New Year. DDW found the atmosphere refreshingly upbeat.  “Going into 2026, there’s a… Read More

#Exclusive Content #Trends & Analysis

#Biopharmaceuticals #GlobalData #Market reporting #Pharmaceutical industry

Top biopharma companies report 4% market growth in Q3 2025

The top 20 global biopharmaceutical companies experienced mixed individual market capitalisation performances in Q3 2025, with those experiencing robust pipeline progress reaping success.   This resulted in a 4% quarter-on-quarter (QoQ) increase in their combined market capitalisation from $3.7 trillion on 30 June 2025 to $3.8 trillion on 30 September 2025,… Read More

#Business & Investment #News #Trends & Analysis

European Commission President Ursula von der Leyen
#Biotech #Biotech hubs #Europe #European Commission #European Union #Market reporting

Can Europe take the lead on biotech?

With uncertainty across the global financial markets and research community, is it Europe’s time to take the lead on biotech? Diana Turner reports.  While biotech has so far been dominated by the US, since the inauguration of Donald Trump in January 2025, there has been considerable uncertainty, with significant cuts… Read More

#Exclusive Content #Market Reports #Trends & Analysis

#In Focus Report #Market reporting #Multiomics

In Focus report: Using multiomics for discovering new drugs

The pharmaceutical industry has changed enormously over time and in more recent years the advancements of technologies that allow a more precise understanding of biological mechanisms has enabled more targeted and precise therapeutics.   Multiomics have been pivotal to this evolvement in the industry, helping teams understand the… Read More

#News

CAR-T cell therapy
#CAR-T #Cell therapy #In Focus Report #Market reporting

In Focus report: Cell therapy and opportunities for new medicines

With significant investment in development and manufacturing, the cell therapy market is expected to boom in the next five years. However, despite the optimism around cell therapies, many are expensive, complicated to manufacture and come with potentially severe side effects. This report investigates how drug developers… Read More

#News